HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Colchicine for epidermolysis bullosa acquisita.

AbstractBACKGROUND:
Epidermolysis bullosa acquisita (EBA) is a chronic subepidermal blistering disease that is difficult to treat. Recently one patient with severe EBA was described who responded dramatically to colchicine.
OBJECTIVE:
Our purpose was to determine the efficacy of colchicine in the treatment of EBA.
METHODS:
Four patients with severe EBA refractory to conventional therapy were treated with colchicine 0.6 to 1.5 mg a day for up to 4 years.
RESULTS:
In all four patients the lessening of skin fragility and the decrease in spontaneous blister formation were dramatic; few side effects were noted.
CONCLUSION:
Colchicine should be considered in the treatment of EBA.
AuthorsB B Cunningham, T T Kirchmann, D Woodley
JournalJournal of the American Academy of Dermatology (J Am Acad Dermatol) Vol. 34 Issue 5 Pt 1 Pg. 781-4 (May 1996) ISSN: 0190-9622 [Print] United States
PMID8632074 (Publication Type: Case Reports, Journal Article)
Chemical References
  • Dermatologic Agents
  • Immunoglobulin G
  • Colchicine
Topics
  • Adult
  • Aged
  • Colchicine (administration & dosage, therapeutic use)
  • Dermatologic Agents (therapeutic use)
  • Diagnosis, Differential
  • Epidermis (pathology)
  • Epidermolysis Bullosa Acquisita (drug therapy, pathology)
  • Female
  • Fluorescent Antibody Technique, Direct
  • Follow-Up Studies
  • Humans
  • Immunoglobulin G (analysis)
  • Male
  • Pemphigoid, Bullous (pathology)
  • Remission Induction
  • Skin (drug effects, pathology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: